Search

Your search keyword '"ISAKA, Shigeo"' showing total 32 results
Start Over Author "ISAKA, Shigeo" Language english
32 results on '"ISAKA, Shigeo"'

4. Prophylactic chemotherapy with intravesical instillation of Adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer

Author

Obata, Koji, Ohashi, Yasuo, Akaza, Hideyuki, Isaka, Shigeo, Kagawa, Susumu, Koiso, Kenkichi, Kotake, Toshihiko, Machida, Tovohei, Matsumura, Yosuke, Niijima, Tadao, Ohe, Hiroshi, Ohi, Yoshitada, Shimazaki, Jun, Tashiro, Kazuya, Ueda, Toyofumi, and The Japanese Urological Cancer Research Group for Adriamycin

Published
1994
Full Text
View/download PDF

7. The 4th study of prophylactic intravesical chemotherapy with Adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese urological cancer research group of Adriamycin

Author

Matsumura, Yosuke, Akaza, Hideyuki, Isaka, Shigeo, Kagawa, Susumu, Koiso, Kenkichi, Kotake, Toshihiko, Machida, Toyohei, Niijima, Tadao, Obata, Koji, Ohashi, Yasuo, Ohe, Hiroshi, Ohi, Yoshitada, Shimazaki, Jun, Tashiro, Kazuya, Ueda, Toyofumi, and the Japanese Urological Cancer Research Group for Adriamycin

Published
1992
Full Text
View/download PDF

8. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer research group for Adriamycin

Author

Akaza, Hideyuki, Koiso, Kenkichi, Kotake, Toshihiko, Matsumura, Yosuke, Isaka, Shigeo, Machida, Toyohei, Obata, Koji, Ohashi, Yasuo, Ohe, Hiroshi, Ohi, Yoshitada, Shimazaki, Jun, Tashiro, Kazuya, Ueda, Toyofumi, Kagawa, Susumu, Niijima, Tadao, and The Japanese Urological Cancer Research Group for Adriamycin

Published
1992
Full Text
View/download PDF

14. Long-term results of a randomized trial for the treatment of stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities

Author

Akakura, Koichiro, Isaka, Shigeo, Akimoto, Susumu, Ito, Haruo, Okada, Kiyoki, Hachiya, Takahiko, Yoshida, Osamu, Arai, Yoichi, Usami, Michiyuki, Kotake, Toshihiko, Tobisu, Ken-Ichi, Ohashi, Yasuo, Sumiyoshi, Yoshiteru, Kakizoe, Tadao, and Shimazaki, Jun

Published
1999
Full Text
View/download PDF

16. Phase III trial of The Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder

Author

Maru, Akio, Akaza, Hideyuki, Isaka, Shigeo, Koiso, Kenkichi, Kotake, Toshihiko, Machida, Toyohei, Matsumura, Yosuke, Nakagami, Yoshizo, Niijima, Tadao, Obata, Koji, Ohe, Hiroshi, Ohi, Yoshitada, Shimazaki, Jun, Tashiro, Kazuya, Ueda, Toyofumi, Uyama, Takeshi, and The Japanese Urological Cancer Research Group for Adriamycin

Published
1987
Full Text
View/download PDF

18. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer: Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group

Author

Akaza, Hideyuki, Isaka, Shigeo, Koiso, Kenkichi, Kotake, Toshihiko, Machida, Toyohei, Maru, Akio, Matsumura, Yosuke, Niijima, Tadao, Obata, Koji, Ohe, Hiroshi, Ohi, Yoshitada, Shimazaki, Jun, Tashiro, Kazuya, Ueda, Toyofumi, Uyama, Takeshi, and The Japanese Urological Cancer Research Group for Adriamycin

Published
1987
Full Text
View/download PDF

19. Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms.

Author

Kato, Tomonori, Komiya, Akira, Yuasa, Joji, Kaga, Kanya, Kaga, Mayuko, Kojima, Satoko, Naya, Yukio, and Isaka, Shigeo

Subjects
ABIRATERONE acetate, DRUG withdrawal symptoms, OLDER patients, CHEST pain treatment, LUMBAR pain, PAIN management
Abstract

A 72-year-old man initially presented with lumbar and right chest pain, but was later found out to also have an elevated prostate-specific antigen (PSA) level at 2,000.0 ng/ml. Further evaluation disclosed metastatic prostate cancer involving the bones and lymph nodes. The patient was initially treated with combined androgen blockade (CAB) with leuprolide acetate and bicalutamide. After 6 months of CAB, the patient's PSA level began to rise from the nadir (85.1 ng/ml) to 113.3 ng/ml. Bicalutamide was withdrawn in anticipation of anti-androgen withdrawal syndrome and the PSA level declined temporally. However, it increased up to 517.0 ng/ml thereafter. Consequently, a year after CAB, abiraterone acetate (AA) was initiated at a standard dose of 1,000 mg daily in combination with 10 mg of prednisolone. PSA rapidly decreased to the nadir of 20.1 ng/ml thereafter. The PSA level remained stable until 2 years after AA administration. However, he decided to reduce the dose of AA to half of the standard dose (500 mg daily). Contrary to our expectations, the serum PSA level promptly decreased to a nadir of 8.1 ng/ml. Thereafter, the PSA level remained stable until 3 years and 9 months after AA administration. Subsequently, the patient stopped taking AA and prednisolone. However, to our surprise, the patient's serum PSA level decreased further to <1.0 ng/ml after AA discontinuation. His PSA remained <1.0 ng/ml without clinical or radiological progression for 1 year after AA withdrawal. Recently, it was reported that cessation of AA is associated with AA withdrawal syndrome in metastatic castration-resistant prostate cancer, defined as a PSA decrease after AA discontinuation, mimicking anti-androgen withdrawal syndrome. In the present study, explanations of the mechanisms underlying this phenomenon were explored, including mutant AR activation by alternative ligands. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

21. Goserelin Acetate with or without Antiandrogen or Estrogen in the Treatment of Patients with Advanced Prostate Cancer: a Multicenter, Randomized, Controlled Trial in Japan.

Author

Kotake, Toshihiko, Usami, Michiyuki, Akaza, Hideyuki, Koiso, Kenkichi, Homma, Yukio, Kawabe, Kazuki, Aso, Yoshio, Orikasa, Seiichi, Shimazaki, Jun, Isaka, Shigeo, Yoshida, Osamu, Hirao, Yoshihiko, Okajima, Eigoro, Naito, Seiji, Kumazawa, Joichi, Kanetake, Hiroshi, Saito, Yutaka, Ohi, Yoshitada, Ohashi, Yasuo, and Group, the Zoladex Study

Published
1999

31. Use of cell-free circulating schistosome DNA in serum, urine, semen, and saliva to monitor a case of refractory imported schistosomiasis hematobia.

Author

Kato-Hayashi N, Yasuda M, Yuasa J, Isaka S, Haruki K, Ohmae H, Osada Y, Kanazawa T, and Chigusa Y

Subjects
Animals, Anthelmintics therapeutic use, Biopsy, DNA, Helminth genetics, Humans, Male, Praziquantel therapeutic use, Saliva parasitology, Schistosoma isolation & purification, Schistosomiasis drug therapy, Semen parasitology, Serum parasitology, Urinary Bladder parasitology, Urine parasitology, Young Adult, DNA, Helminth isolation & purification, Drug Monitoring methods, Parasitology methods, Schistosomiasis diagnosis, Schistosomiasis parasitology
Abstract

This case of imported refractory schistosomiasis has highlighted the usefulness of cell-free parasite DNA as a diagnostic marker to assess active schistosome infection. In contrast to the rapid disappearance of ova in urine, parasite DNA remained persistent in several other specimen types even after the fourth treatment with praziquantel. This result was consistent with the presence of morphologically intact ova in bladder biopsy samples and with the corresponding symptoms.

Published
2013
Full Text
View/download PDF

32. Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method.

Author

Kinsui H, Ueda T, Suzuki H, Isaka S, Sekita N, Komiya A, Tobe T, Yamanishi T, Akakura K, Ichikawa T, Igarashi T, and Ito H

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell pathology, Disease-Free Survival, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoblotting, Kidney enzymology, Kidney Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Neovascularization, Pathologic, Prognosis, Carcinoma, Renal Cell enzymology, Kidney Neoplasms enzymology, Thymidine Phosphorylase metabolism
Abstract

Thymidine phosphorylase (TP) expression in 100 paired samples of renal cell carcinoma (RCC) and normal adjacent tissue was analyzed by an ELISA method. We also investigated whether TP expression correlates with clinicopathological findings and clinical outcomes of these patients. Median TP expression was 9-fold (range, 0.5-56) higher in primary tumor than in non-cancerous renal tissue (P < 0.0001). There was a significant difference with respect to tumor venous invasion. TP expression was significantly higher in patients with such venous invasion than in those without (P = 0.018). However, there was no correlation between TP level and other clinicopathological findings and the survival curves. These results suggest that ELISA is useful for evaluating TP expression of human RCC and may provide a novel approach to therapy for patients with RCC.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results